Introduction: Although current guidelines recommend against routine antibiotic prescription for acute exacerbation of bronchial asthma, children with acute exacerbation of asthma receive antibiotic treatment more frequently. In addition, those antibiotics are often prescribed only for exacerbation of asthma without concurrent bacterial infection. Objective: To clarify the association between antibiotic treatment and bacterial colonization in acute exacerbation of asthma, we investigated whether or not antibiotics affect the clinical condition, laboratory findings, and pharyngeal bacterial colonization in those patients. Methods: Potential bacterial pathogens were investigated in pharyngeal samples of 111 children with acute exacerbation of asthma (mean/median age: 2.8/2.6 years old, respectively). We collected clinical data, such as the duration of wheezing and antibiotic use, and measured the peripheral white blood cell counts, C-reactive protein, and serum levels of total and allergen-specific IgE. Results: Antibiotics were used in 50.5% patients with acute asthma exacerbation and included cephalosporin, penicillin, macrolide, and others. Episodes of wheezing were significantly longer in patients with antibiotic treatment than in those without it (6.7 ± 3.6 days vs. 6.0 ± 3.1, p = 0.044). Similarly, episodes of wheezing were significantly longer in moderate exacerbation patients with antibiotics than in those without them. Furthermore, in patients with Streptococcus pneumoniae, antibiotic treatment was associated with an extended duration of wheezing in cases of acute moderate exacerbation (7.0 ± 2.4 days vs. 4.8 ± 4.1, p = 0.043). Conclusions: These results suggest that antibiotic treatment in acute exacerbation of asthma might lead to longer asthmatic symptoms, specifically in patients with pharyngeal S. pneumoniae colonization.

Keywords:
Asthma, Antibiotics, Bacterial colonization, Childhood, Streptococcus pneumoniae
1.
Abe K, Miyawaki A, Nakamura M, Ninomiya H, Kobayashi Y. Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan.
J Allergy Clin Immunol Pract
. 2021 Jan;9(1):494–6.e1.
2.
De Boeck K, Vermeulen F, Meyts I, Hutsebaut L, Franckaert D, Proesmans M. Coprescription of antibiotics and asthma drugs in children.
Pediatrics
. 2011 Jun;127(6):1022–6.
3.
Baan EJ, Janssens HM, Kerckaert T, Bindels PJE, de Jongste JC, Sturkenboom MCJM, et al. Antibiotic use in children with asthma: cohort study in UK and Dutch primary care databases.
BMJ Open
. 2018 Nov;8(11):e022979.
4.
Fong I, Zhu J, Finkelstein Y, To T. Antibiotic use in children and youths with asthma: a population-based case-control study.
ERJ Open Res
. 2021 Mar;7(1):00944–2020.
5.
Murray CS, Lucas SJ, Blakey J, Kaplan A, Papi A, Paton J, et al. A real-life comparative effectiveness study into the addition of antibiotics to the management of asthma exacerbations in primary care.
Eur Respir J
. 2021 Jul;58(1):2003599.
6.
Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB, et al. The effect of telithromycin in acute exacerbations of asthma.
N Engl J Med
. 2006 Apr;354(15):1589–600.
7.
Koutsoubari I, Papaevangelou V, Konstantinou GN, Makrinioti H, Xepapadaki P, Kafetzis D, et al. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study.
Pediatr Allergy Immunol
. 2012 Jun;23(4):385–90.
8.
Kama Y, Kato M, Yamada Y, Koike T, Suzuki K, Enseki M, et al. The suppressive role of Streptococcus pneumoniae colonization in acute exacerbations of childhood bronchial asthma.
Int Arch Allergy Immunol
. 2020;181(3):191–9.
9.
Arakawa H, Hamasaki Y, Kohno Y, Ebisawa M, Kondo N, Nishima S, et al. Japanese guidelines for childhood asthma 2017.
Allergol Int
. 2017 Apr;66(2):190–204.
10.
Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, et al., editors.
Manual of clinical microbiology
. 11th ed. Washington, DC: American Society for Microbiology; 2015.
11.
Kato M, Tsukagoshi H, Yoshizumi M, Saitoh M, Kozawa K, Yamada Y, et al. Different cytokine profile and eosinophil activation are involved in rhinovirus- and RS virus-induced acute exacerbation of childhood wheezing.
Pediatr Allergy Immunol
. 2011 Feb;22(1 Pt 2):e87–94.
12.
Burrell A, Foy C, Burns M. Applicability of three alternative instruments for food authenticity analysis: GMO identification.
Biotechnol Res Int
. 2011 Mar;2011:838232.
13.
Kato M, Yamada Y, Maruyama K, Hayashi Y. Age at onset of asthma and allergen sensitization early in life.
Allergol Int
. 2014 May;63 Suppl 1:23–8.
14.
Lindenauer PK, Stefan MS, Feemster LC, Shieh MS, Carson SS, Au DH, et al. Use of antibiotics among patients hospitalized for exacerbations of asthma.
JAMA Intern Med
. 2016 Sep;176(9):1397–400.
15.
Okubo Y, Horimukai K, Michihata N, Morita K, Matsui H, Fushimi K, et al. Association between early antibiotic treatment and clinical outcomes in children hospitalized for asthma exacerbation.
J Allergy Clin Immunol
. 2021 Jan;147(1):114–22.e14.
16.
Stefan MS, Shieh MS, Spitzer KA, Pekow PS, Krishnan JA, Au DH, et al. Association of antibiotic treatment with outcomes in patients hospitalized for an asthma exacerbation treated with systemic corticosteroids.
JAMA Intern Med
. 2019 Mar;179(3):333–9.
17.
Shapiro GG, Eggleston PA, Pierson WE, Ray CG, Bierman CW. Double-blind study of the effectiveness of a broad spectrum antibiotic in status asthmaticus.
Pediatrics
. 1974 Jun;53(6):867–72.
18.
Graham VA, Milton AF, Knowles GK, Davies RJ. Routine antibiotics in hospital management of acute asthma.
Lancet
. 1982 Feb;1(8269):418–20.
19.
Fonseca-Aten M, Okada PJ, Bowlware KL, Chavez-Bueno S, Mejias A, Rios AM, et al. Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.
Ann Allergy Asthma Immunol
. 2006 Oct;97(4):457–63.
20.
Johnston SL, Szigeti M, Cross M, Brightling C, Chaudhuri R, Harrison T, et al. Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial.
JAMA Intern Med
. 2016 Nov;176(11):1630–7.
21.
Douglas LC, Choi J, Esteban-Cruciani N. Azithromycin treatment in children hospitalized with asthma: a retrospective cohort study.
J Asthma
. 2020 May;57(5):525–31.
22.
Preston JA, Essilfie AT, Horvat JC, Wade MA, Beagley KW, Gibson PG, et al. Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae.
Vaccine
. 2007 Nov;25(48):8154–62.
23.
Thorburn AN, Tseng HY, Donovan C, Hansbro NG, Jarnicki AG, Foster PS, et al. TLR2, TLR4 and MyD88 mediate allergic airway disease (AAD) and Streptococcus pneumoniae-induced suppression of AAD.
PLoS One
. 2016 Jun;11(6):e0156402.
© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.